A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension

被引:13
作者
Fristrom, B
Nilsson, SEG
机构
[1] Department of Ophthalmology, University of Linköping, Linköping
关键词
D O I
10.1136/bjo.81.10.867
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Aim-To compare the intraocular pressure (IOP) reducing effect of latanoprost 0.005% and 0.001%. Methods-Twenty four patients with glaucoma or ocular hypertension were randomised into two groups. Twelve patients (group 1) were given latanoprost 0.005% once daily for 4 weeks and then latanoprost 0.001% once daily for the following 4 weeks. Twelve patients (group 2) were given latanoprost 0.001% once daily for 4 weeks and then latanoprost 0.005% for the following 4 weeks. Results-There was a significant IOP reduction from baseline in both groups on day 28 as well as on day 56. When the results from both groups were used for calculations, the mean IOP reduction from baseline after 4 weeks of treatment with latanoprost 0.005% (day 28 or 56) was 9.6 (SD 3.3) mm Hg (35.0%). After 4 weeks of treatment with latanoprost 0.001%, the IOP reduction (day 28 or 56) was 7.6 (3.4) mm Hg (27.7%). The difference in IOP reduction between the two concentrations was 2.0 (2.3) mm Hg (p<0.001). Conclusions-Latanoprost 0.005% was more effective than latanoprost 0.001% in reducing IOP. Even the lower concentration was surprisingly effective, and potentially may be of importance for use in clinical practice. Furthermore, it is at present unknown whether the increase in iris pigmentation seen in certain patients treated with latanoprost 0.005% is dose dependent and might be less pronounced with latanoprost 0.001%. Long term studies with a larger number of patients are required in order to answer this question.
引用
收藏
页码:867 / 870
页数:4
相关论文
共 15 条
[1]   PHXA34, A NEW POTENT OCULAR HYPOTENSIVE DRUG - A STUDY ON DOSE-RESPONSE RELATIONSHIP AND ON AQUEOUS-HUMOR DYNAMICS IN HEALTHY-VOLUNTEERS [J].
ALM, A ;
VILLUMSEN, J .
ARCHIVES OF OPHTHALMOLOGY, 1991, 109 (11) :1564-1568
[2]  
ALM A, 1993, OPHTHALMOLOGY, V100, P1312
[3]   LATANOPROST ADMINISTERED ONCE-DAILY CAUSED A MAINTAINED REDUCTION OF INTRAOCULAR-PRESSURE IN GLAUCOMA PATIENTS TREATED CONCOMITANTLY WITH TIMOLOL [J].
ALM, A ;
WIDENGARD, I ;
KJELLGREN, D ;
SODERSTROM, M ;
FRISTROM, B ;
HEIJL, A ;
STJERSCHANTZ, J .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1995, 79 (01) :12-16
[4]   Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning - A comparison with timolol [J].
Alm, A ;
Stjernschantz, J ;
Widengard, I ;
Linden, C ;
Soderstrom, M ;
Nilsson, SE ;
Fristrom, B ;
Lindblom, B ;
Heijl, A ;
Gundersen, KG ;
Ehinger, B ;
Holmin, C ;
BengtssonStigmar, E ;
Aasved, H ;
Jangard, P ;
Ringvold, A ;
Vegge, T ;
Halseide, R ;
LundAndersen, H ;
Flesner, P ;
Thygesen, J ;
Airaksinen, J ;
Tuulonen, A .
OPHTHALMOLOGY, 1995, 102 (12) :1743-1752
[5]   Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma - A six-month, masked, multicenter trial in the United States [J].
Camras, CB ;
Cioffi, GA ;
VanBuskirk, EM ;
Fraser, J ;
Stewart, WC ;
Stewart, JA ;
Lustgarten, J ;
Schumer, RA ;
Podos, SM ;
Arroyo, M ;
Nitzberg, S ;
Ritch, R ;
Abundo, G ;
Caronia, R ;
Liebmann, J ;
Steinberger, D ;
Krupin, T ;
Rosenberg, LF ;
Ruderman, JM ;
Clarkson, K ;
Weinreb, RN ;
Ochabsi, R ;
Sherwood, M ;
Smith, MF ;
Stokes, DW ;
Zam, ZS ;
Wilensky, J ;
Hillman, D ;
Kaplan, B ;
Gates, V ;
Nail, C ;
Zimmerman, T ;
Fechtner, R ;
Fenton, R ;
Fenton, J ;
Higginbotham, EJ ;
Johnson, AT ;
PollackRundle, CJ ;
Weiss, E ;
Yablonski, ME ;
Tannenbaum, MH ;
Ibrahim, F ;
Ohia, E ;
Neely, D ;
Minckler, D ;
Heuer, D ;
Lee, P ;
Padea, M ;
Kaufman, PL ;
Heatley, GA .
OPHTHALMOLOGY, 1996, 103 (01) :138-147
[6]   INTRAOCULAR-PRESSURE REDUCTION WITH PHXA34, A NEW PROSTAGLANDIN ANALOG, IN PATIENTS WITH OCULAR HYPERTENSION [J].
CAMRAS, CB ;
SCHUMER, RA ;
MARSK, A ;
LUSTGARTEN, JS ;
SERLE, JB ;
STJERNSCHANTZ, J ;
BITO, LZ ;
PODOS, SM .
ARCHIVES OF OPHTHALMOLOGY, 1992, 110 (12) :1733-1738
[7]   INTERACTION OF PHXA41, A NEW PROSTAGLANDIN ANALOG, WITH PILOCARPINE - A STUDY ON PATIENTS WITH ELEVATED INTRAOCULAR-PRESSURE [J].
FRISTROM, B ;
NILSSON, SEG .
ARCHIVES OF OPHTHALMOLOGY, 1993, 111 (05) :662-665
[8]   PROSTAGLANDIN-F-2-ALPHA INCREASES UVEOSCLERAL OUTFLOW IN THE CYNOMOLGUS MONKEY [J].
GABELT, BT ;
KAUFMAN, PL .
EXPERIMENTAL EYE RESEARCH, 1989, 49 (03) :389-402
[9]  
NAGASUBRAMANIAN S, 1993, OPHTHALMOLOGY, V100, P1305
[10]   INCREASED UVEOSCLERAL OUTFLOW AS A POSSIBLE MECHANISM OF OCULAR HYPOTENSION CAUSED BY PROSTAGLANDIN F-2-ALPHA-1-ISOPROPYLESTER IN THE CYNOMOLGUS MONKEY [J].
NILSSON, SFE ;
SAMUELSSON, M ;
BILL, A ;
STJERNSCHANTZ, J .
EXPERIMENTAL EYE RESEARCH, 1989, 48 (05) :707-716